Session » Immunological Complications of Medical Therapy Poster
-
Abstract Number: 0752
A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis
-
Abstract Number: 0753
Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study
-
Abstract Number: 0754
Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure
-
Abstract Number: 0755
Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
-
Abstract Number: 0756
Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and the Effect of Pre-existing Autoimmune and Non-immune Mediated Rheumatic Conditions
-
Abstract Number: 0757
Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases
-
Abstract Number: 0758
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
-
Abstract Number: 0759
Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study
-
Abstract Number: 0760
Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors
-
Abstract Number: 0761
Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group
-
Abstract Number: 0762
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
-
Abstract Number: 0763
Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
-
Abstract Number: 0764
No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors
-
Abstract Number: 0766
CCP+ Immune Checkpoint Inhibitor Arthritis Patients Have Less ACPA Epitope Expansion Than CCP+ Rheumatoid Arthritis Patients
-
Abstract Number: 0767
Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) – A Retrospective Chart Review Study of Adults with Inflammatory Arthritis Associated with Cancer Immunotherapies
-
Abstract Number: 0768
Reevaluating Clinical Outcomes of Patients on Combination Biologics
-
Abstract Number: 0769
Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
-
Abstract Number: 0770
Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies
-
Abstract Number: 0771
The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
-
Abstract Number: 0772
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
-
Abstract Number: 0773
Additional Dose of SARS-CoV-2 Vaccine Improves Cross-Variant Neutralization Titers in Immunosuppressed Patients with Chronic Inflammatory Disease
-
Abstract Number: 0774
HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
-
Abstract Number: 0775
The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment
-
Abstract Number: 0776
Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey